vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and OPPENHEIMER HOLDINGS INC (OPY). Click either name above to swap in a different company.
OPPENHEIMER HOLDINGS INC is the larger business by last-quarter revenue ($472.6M vs $247.1M, roughly 1.9× ANI PHARMACEUTICALS INC). OPPENHEIMER HOLDINGS INC runs the higher net margin — 15.7% vs 11.1%, a 4.6% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 25.9%). OPPENHEIMER HOLDINGS INC produced more free cash flow last quarter ($183.6M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 15.7%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Oppenheimer Holdings Inc. is an American multinational independent investment bank and financial services company offering investment banking, financial advisory services, capital markets services, asset management, wealth management, and related products and services worldwide. The company, which once occupied the One World Financial Center building in Manhattan, now bases its operations at 85 Broad Street in New York City.
ANIP vs OPY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $472.6M |
| Net Profit | $27.5M | $74.4M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 22.4% |
| Net Margin | 11.1% | 15.7% |
| Revenue YoY | 29.6% | 25.9% |
| Net Profit YoY | 367.5% | 593.1% |
| EPS (diluted) | $1.14 | $6.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $472.6M | ||
| Q3 25 | $227.8M | $424.4M | ||
| Q2 25 | $211.4M | $373.2M | ||
| Q1 25 | $197.1M | $367.8M | ||
| Q4 24 | $190.6M | $375.4M | ||
| Q3 24 | $148.3M | $373.4M | ||
| Q2 24 | $138.0M | $330.6M | ||
| Q1 24 | $137.4M | $353.1M |
| Q4 25 | $27.5M | $74.4M | ||
| Q3 25 | $26.6M | $21.7M | ||
| Q2 25 | $8.5M | $21.7M | ||
| Q1 25 | $15.7M | $30.7M | ||
| Q4 24 | $-10.3M | $10.7M | ||
| Q3 24 | $-24.2M | $24.5M | ||
| Q2 24 | $-2.3M | $10.3M | ||
| Q1 24 | $18.2M | $26.1M |
| Q4 25 | 14.1% | 22.4% | ||
| Q3 25 | 15.9% | 7.5% | ||
| Q2 25 | 6.6% | 8.6% | ||
| Q1 25 | 13.3% | 11.2% | ||
| Q4 24 | -2.3% | 4.5% | ||
| Q3 24 | -13.8% | 9.5% | ||
| Q2 24 | 3.7% | 4.8% | ||
| Q1 24 | 14.8% | 10.6% |
| Q4 25 | 11.1% | 15.7% | ||
| Q3 25 | 11.7% | 5.1% | ||
| Q2 25 | 4.0% | 5.8% | ||
| Q1 25 | 8.0% | 8.3% | ||
| Q4 24 | -5.4% | 2.9% | ||
| Q3 24 | -16.3% | 6.6% | ||
| Q2 24 | -1.7% | 3.1% | ||
| Q1 24 | 13.2% | 7.4% |
| Q4 25 | $1.14 | $6.51 | ||
| Q3 25 | $1.13 | $1.90 | ||
| Q2 25 | $0.36 | $1.91 | ||
| Q1 25 | $0.69 | $2.72 | ||
| Q4 24 | $-0.45 | $0.92 | ||
| Q3 24 | $-1.27 | $2.16 | ||
| Q2 24 | $-0.14 | $0.92 | ||
| Q1 24 | $0.82 | $2.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $38.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $983.8M |
| Total Assets | $1.4B | $3.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $38.4M | ||
| Q3 25 | $262.6M | $38.3M | ||
| Q2 25 | $217.8M | $37.6M | ||
| Q1 25 | $149.8M | $36.7M | ||
| Q4 24 | $144.9M | $33.1M | ||
| Q3 24 | $145.0M | $32.2M | ||
| Q2 24 | $240.1M | $33.2M | ||
| Q1 24 | $228.6M | $27.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $112.8M | ||
| Q2 24 | — | $112.8M | ||
| Q1 24 | — | $112.7M |
| Q4 25 | $540.7M | $983.8M | ||
| Q3 25 | $505.8M | $920.3M | ||
| Q2 25 | $436.8M | $896.9M | ||
| Q1 25 | $418.6M | $872.3M | ||
| Q4 24 | $403.7M | $850.4M | ||
| Q3 24 | $405.9M | $837.8M | ||
| Q2 24 | $455.8M | $812.1M | ||
| Q1 24 | $452.0M | $801.5M |
| Q4 25 | $1.4B | $3.7B | ||
| Q3 25 | $1.4B | $3.8B | ||
| Q2 25 | $1.3B | $3.7B | ||
| Q1 25 | $1.3B | $3.6B | ||
| Q4 24 | $1.3B | $3.4B | ||
| Q3 24 | $1.3B | $3.4B | ||
| Q2 24 | $920.8M | $3.3B | ||
| Q1 24 | $914.5M | $3.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $188.8M |
| Free Cash FlowOCF − Capex | $29.1M | $183.6M |
| FCF MarginFCF / Revenue | 11.8% | 38.8% |
| Capex IntensityCapex / Revenue | 0.5% | 1.1% |
| Cash ConversionOCF / Net Profit | 1.10× | 2.54× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $191.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $188.8M | ||
| Q3 25 | $44.1M | $63.4M | ||
| Q2 25 | $75.8M | $40.1M | ||
| Q1 25 | $35.0M | $-91.7M | ||
| Q4 24 | $15.9M | $-108.2M | ||
| Q3 24 | $12.5M | $11.4M | ||
| Q2 24 | $17.4M | $-115.3M | ||
| Q1 24 | $18.3M | $-79.0M |
| Q4 25 | $29.1M | $183.6M | ||
| Q3 25 | $38.0M | $62.2M | ||
| Q2 25 | $71.8M | $38.9M | ||
| Q1 25 | $32.5M | $-93.4M | ||
| Q4 24 | $13.5M | $-113.3M | ||
| Q3 24 | $7.7M | $11.2M | ||
| Q2 24 | $13.0M | $-116.7M | ||
| Q1 24 | $13.7M | $-79.3M |
| Q4 25 | 11.8% | 38.8% | ||
| Q3 25 | 16.7% | 14.7% | ||
| Q2 25 | 34.0% | 10.4% | ||
| Q1 25 | 16.5% | -25.4% | ||
| Q4 24 | 7.1% | -30.2% | ||
| Q3 24 | 5.2% | 3.0% | ||
| Q2 24 | 9.4% | -35.3% | ||
| Q1 24 | 10.0% | -22.5% |
| Q4 25 | 0.5% | 1.1% | ||
| Q3 25 | 2.7% | 0.3% | ||
| Q2 25 | 1.9% | 0.3% | ||
| Q1 25 | 1.3% | 0.5% | ||
| Q4 24 | 1.3% | 1.4% | ||
| Q3 24 | 3.2% | 0.1% | ||
| Q2 24 | 3.2% | 0.4% | ||
| Q1 24 | 3.3% | 0.1% |
| Q4 25 | 1.10× | 2.54× | ||
| Q3 25 | 1.66× | 2.92× | ||
| Q2 25 | 8.87× | 1.85× | ||
| Q1 25 | 2.23× | -2.99× | ||
| Q4 24 | — | -10.08× | ||
| Q3 24 | — | 0.47× | ||
| Q2 24 | — | -11.23× | ||
| Q1 24 | 1.00× | -3.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
OPY
| Advisory Fees | $166.6M | 35% |
| Capital Markets Segment | $155.5M | 33% |
| Other | $57.2M | 12% |
| Commissions From Sales And Trading | $52.9M | 11% |
| Bank Deposit Sweep Income | $27.7M | 6% |
| Mutual Fund Income | $8.9M | 2% |
| Investment Banking Capital Markets | $3.3M | 1% |
